Royalty Pharma (RPRX) Income from Non-Controlling Interests (2019 - 2026)

Royalty Pharma (RPRX) has 8 years of Income from Non-Controlling Interests data on file, last reported at $173.6 million in Q1 2026.

• For the quarter ending Q1 2026, Income from Non-Controlling Interests fell 11.03% year-over-year to $173.6 million; the trailing twelve-month figure through Mar 2026 stood at $491.0 million (down 27.37% YoY), and the FY2025 full-year result was $553.2 million, up 17.26% from the prior year.
• Income from Non-Controlling Interests grew to $173.6 million in Q1 2026, from $141.7 million in the prior quarter.
• In the past five years, Income from Non-Controlling Interests ranged from a high of $262.4 million in Q3 2024 to a low of -$153.9 million in Q4 2022.
• A 5-year average of $112.4 million and a median of $126.1 million in 2024 frame the typical range for Income from Non-Controlling Interests.
• Across the five-year window, Income from Non-Controlling Interests plunged 436.37% in 2022 and soared 2255.39% in 2025, its largest moves.
• Tracing RPRX's Income from Non-Controlling Interests over 5 years: stood at -$153.9 million in 2022, then soared by 245.02% to $223.2 million in 2023, then plunged by 43.5% to $126.1 million in 2024, then rose by 12.34% to $141.7 million in 2025, then climbed by 22.48% to $173.6 million in 2026.
• Business Quant data shows RPRX's Income from Non-Controlling Interests at $173.6 million in Q1 2026, $141.7 million in Q4 2025, and $156.0 million in Q3 2025.